source
- AstraZeneca attributes Phase 3 failure of bone disease enzyme therapy to trial design flawsAstraZeneca disclosed that its Phase 3 study of an enzyme replacement therapy for a rare genetic bone disorder did not meet its primary objectives. The company said the shortfall was largely due t…
- Americans show higher trust in science than most countries, survey findsA new Wellcome Global Monitor survey of people in 140 countries found that 52% of Americans say they have a lot of trust in science, compared with just 26% globally. Only 40% of Americans reported…